Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 31
Filter
1.
Redox Biol ; 64: 102769, 2023 08.
Article in English | MEDLINE | ID: covidwho-2328371

ABSTRACT

Cholesterol-24-hydroxylase (CH24H or Cyp46a1) is a reticulum-associated membrane protein that plays an irreplaceable role in cholesterol metabolism in the brain and has been well-studied in several neuro-associated diseases in recent years. In the present study, we found that CH24H expression can be induced by several neuroinvasive viruses, including vesicular stomatitis virus (VSV), rabies virus (RABV), Semliki Forest virus (SFV) and murine hepatitis virus (MHV). The CH24H metabolite, 24-hydroxycholesterol (24HC), also shows competence in inhibiting the replication of multiple viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 24HC can increase the cholesterol concentration in multivesicular body (MVB)/late endosome (LE) by disrupting the interaction between OSBP and VAPA, resulting in viral particles being trapped in MVB/LE, ultimately compromising VSV and RABV entry into host cells. These findings provide the first evidence that brain cholesterol oxidation products may play a critical role in viral infection.


Subject(s)
Virus Internalization , Animals , Mice , Cholesterol/metabolism , COVID-19/metabolism , COVID-19/virology , Homeostasis , SARS-CoV-2/metabolism , Cholesterol 24-Hydroxylase/metabolism
2.
Adv Sci (Weinh) ; 10(17): e2207249, 2023 06.
Article in English | MEDLINE | ID: covidwho-2299008

ABSTRACT

Highly pathogenic coronavirus (CoV) infection induces a defective innate antiviral immune response coupled with the dysregulated release of proinflammatory cytokines and finally results in acute respiratory distress syndrome (ARDS). A timely and appropriate triggering of innate antiviral response is crucial to inhibit viral replication and prevent ARDS. However, current medical countermeasures can rarely meet this urgent demand. Here, an antiviral nanobiologic named CoVR-MV is developed, which is polymerized of CoVs receptors based on a biomimetic membrane vesicle system. The designed CoVR-MV interferes with the viral infection by absorbing the viruses with maximized viral spike target interface, and mediates the clearance of the virus through its inherent interaction with macrophages. Furthermore, CoVR-MV coupled with the virus promotes a swift production and signaling of endogenous type I interferon via deregulating 7-dehydrocholesterol reductase (DHCR7) inhibition of interferon regulatory factor 3 (IRF3) activation in macrophages. These sequential processes re-modulate the innate immune responses to the virus, trigger spontaneous innate antiviral defenses, and rescue infected Syrian hamsters from ARDS caused by SARS-CoV-2 and all tested variants.


Subject(s)
COVID-19 , Respiratory Distress Syndrome , Humans , SARS-CoV-2 , Immunity, Innate , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use
3.
Cell Mol Immunol ; 20(4): 351-364, 2023 04.
Article in English | MEDLINE | ID: covidwho-2287148

ABSTRACT

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced cytokine storm is closely associated with coronavirus disease 2019 (COVID-19) severity and lethality. However, drugs that are effective against inflammation to treat lethal COVID-19 are still urgently needed. Here, we constructed a SARS-CoV-2 spike protein-specific CAR, and human T cells infected with this CAR (SARS-CoV-2-S CAR-T) and stimulated with spike protein mimicked the T-cell responses seen in COVID-19 patients, causing cytokine storm and displaying a distinct memory, exhausted, and regulatory T-cell phenotype. THP1 remarkably augmented cytokine release in SARS-CoV-2-S CAR-T cells when they were in coculture. Based on this "two-cell" (CAR-T and THP1 cells) model, we screened an FDA-approved drug library and found that felodipine, fasudil, imatinib, and caspofungin were effective in suppressing the release of cytokines, which was likely due to their ability to suppress the NF-κB pathway in vitro. Felodipine, fasudil, imatinib, and caspofungin were further demonstrated, although to different extents, to attenuate lethal inflammation, ameliorate severe pneumonia, and prevent mortality in a SARS-CoV-2-infected Syrian hamster model, which were also linked to their suppressive role in inflammation. In summary, we established a SARS-CoV-2-specific CAR-T-cell model that can be utilized as a tool for anti-inflammatory drug screening in a fast and high-throughput manner. The drugs identified herein have great potential for early treatment to prevent COVID-19 patients from cytokine storm-induced lethality in the clinic because they are safe, inexpensive, and easily accessible for immediate use in most countries.


Subject(s)
COVID-19 , Receptors, Chimeric Antigen , Humans , SARS-CoV-2/metabolism , Imatinib Mesylate/pharmacology , Imatinib Mesylate/therapeutic use , Caspofungin , Felodipine , Cytokine Release Syndrome/drug therapy , Inflammation , Cytokines/metabolism
4.
Cell Host Microbe ; 2022 Oct 18.
Article in English | MEDLINE | ID: covidwho-2237104

ABSTRACT

SARS-CoV-2 spread in humans results in continuous emergence of new variants, highlighting the need for vaccines with broad-spectrum antigenic coverage. Using inter-lineage chimera and mutation-patch strategies, we engineered a recombinant monomeric spike variant (STFK1628x) that contains key regions and residues across multiple SAR-CoV-2 variants. STFK1628x demonstrated high immunogenicity and mutually complementary antigenicity to its prototypic form (STFK). In hamsters, a bivalent vaccine composed of STFK and STFK1628x elicited high titers of broad-spectrum neutralizing antibodies to 19 circulating SARS-CoV-2 variants, including Omicron sublineages BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, and BA.4/5. Furthermore, this vaccine conferred robust protection against intranasal challenges by either SARS-CoV-2 ancestral strain or immune-evasive Beta and Omicron BA.1. Strikingly, vaccination with the bivalent vaccine in hamsters effectively blocked within-cage virus transmission of ancestral SARS-CoV-2, Beta variant, and Omicron BA.1 to unvaccinated sentinels. Thus, our study provided insight and antigen candidates for the development of next-generation COVID-19 vaccines.

5.
J Virol ; 97(2): e0168422, 2023 02 28.
Article in English | MEDLINE | ID: covidwho-2193454

ABSTRACT

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant is becoming a dominant circulator and has several mutations in the spike glycoprotein, which may cause shifts of immunogenicity, so as to result in immune escape and breakthrough infection among the already infected or vaccinated populations. It is unclear whether infection with Omicron could generate adequate cross-variant protection. To investigate this possibility, we used Syrian hamsters as an animal model for infection of SARS-CoV-2. The serum from Omicron BA.1 variant-infected hamsters showed a significantly lower neutralization effect against infection of the same or different SARS-CoV-2 variants than the serum from Beta variant-infected hamsters. Furthermore, the serum from Omicron BA.1 variant-infected hamsters were insufficient to protect against rechallenge of SARS-CoV-2 Prototype, Beta and Delta variants and itself. Importantly, we found that rechallenge with different SARS-CoV-2 lineages elevated cross-variant serum neutralization titers. Overall, our findings indicate a weakened immunogenicity feature of Omicron BA.1 variant that can be overcome by rechallenge of a different SARS-CoV-2 lineages. Our results may lead to a new guideline in generation and use of the vaccinations to combat the pandemic of SARS-CoV-2 Omicron variant and possible new variants. IMPORTANCE The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant causes breakthrough infections among convalescent patients and vaccinated populations. However, Omicron does not generate robust cross-protective responses. Here, we investigate whether heterologous SARS-CoV-2 challenge is able to enhance antibody response in a sensitive animal model, namely, Syrian hamster. Of note, a heterologous challenge of Beta and Omicron BA.1 variant significantly broadens the breadth of SARS-CoV-2 neutralizing responses against the prototype, Beta, Delta, and Omicron BA.1 variants. Our findings confirm that vaccination strategy with heterologous antigens might be a good option to protect against the evolving SARS-CoV-2.


Subject(s)
COVID-19 , SARS-CoV-2 , Animals , Cricetinae , Antibodies, Neutralizing , Antibodies, Viral , Antigens, Heterophile/immunology , Breakthrough Infections , COVID-19/prevention & control , Mesocricetus , SARS-CoV-2/genetics , SARS-CoV-2/immunology , Spike Glycoprotein, Coronavirus/genetics , Immunogenicity, Vaccine
6.
Int J Environ Res Public Health ; 19(22)2022 Nov 17.
Article in English | MEDLINE | ID: covidwho-2116276

ABSTRACT

The purpose of this study was to compare the variability in quality of life in the area of digital consumption among older adults in urban and rural China during the COVID-19 pandemic. This study proposed a low-cost mixed research method, and the methodology used a quantitative study of a large regional sample combined with a qualitative study of a small regional sample. Data for the large-scale area sample were obtained from the China family panel study (CFPS) dataset, and data for the small-scale regional sample were obtained from Nanjing, China. The quantitative analysis of the large-scale regional sample used the least squares regression analysis (OSL) and propensity score matching (PSM). The qualitative analysis of the small-scale regional sample used the selection optimization and compensation (SOC) model. The findings show that economic income is a direct driver of digital consumption. Digital consumption had a significant positive relationship with the quality of life for urban and rural older adults. In addition, the study established the semantic network relationships of the coping strategies of digital consumption of older adults and their drivers. Finally, the theoretical and practical implications of these findings are discussed in the context of other related studies.


Subject(s)
COVID-19 , Physiological Phenomena , Humans , Aged , Quality of Life , Pandemics , COVID-19/epidemiology , China
7.
iScience ; 25(12): 105475, 2022 Dec 22.
Article in English | MEDLINE | ID: covidwho-2095531

ABSTRACT

Recently, a new variant lineage of SARS-CoV-2, namely Omicron, became the dominant global circulating strain. The multiple antigenic mutations of Omicron largely decrease the efficiency of current vaccines and neutralizing antibodies, which highlights the need for more potent and reachable medical countermeasures. Here, we hypothesize that direct viral clearance by nasal irrigation might be a convenient and alternative option, and perform proof-of-concept experiments in the Syrian hamster model. Interestingly, Omicron shows a different dynamic in the changes of viral RNA, viral titers, and proinflammatory cytokines in nasal rinsing samples when compared with the prototype. Meanwhile, the levels of viral load and proinflammatory cytokines in nasal rinsing samples can indicate the severity of lung injury. Of note, daily nasal irrigation efficiently attenuates inflammation and lung injury in Omicron-infected hamsters by decreasing the viral loads in the respiratory tract organs. Moreover, daily nasal irrigation effectively suppresses viral transmission by close contact.

8.
Medicine ; 2(4):289-292, 2022.
Article in English | EuropePMC | ID: covidwho-2092397

ABSTRACT

Severe acute respiratory syndrome coronavirus-2 infection is usually self-limited, with a short duration for viral shedding within several weeks. However, prolonged viral shedding has been observed in severe or immune-compromised coronavirus disease 2019 (COVID-19) cases. Here, we reported that three young adult cases of COVID-19 patients, who were either immunosuppressed nor severe, showed prolonged viral RNA shedding from the upper respiratory tract for 58, 81, and 137 days since initial diagnosis. To our knowledge, this is the longest duration of viral shedding reported to date in young adult patients. Further studies on factors relevant to prolonged viral positivity, as well as the correlation between viral positivity and transmission risk are needed for the optimal management of COVID-19 patients with prolonged nucleic acid positive.

9.
PLoS Pathog ; 18(10): e1010636, 2022 10.
Article in English | MEDLINE | ID: covidwho-2079775

ABSTRACT

Wastewater-based epidemiology (WBE) is an effective way of tracking the appearance and spread of SARS-COV-2 lineages through communities. Beginning in early 2021, we implemented a targeted approach to amplify and sequence the receptor binding domain (RBD) of SARS-COV-2 to characterize viral lineages present in sewersheds. Over the course of 2021, we reproducibly detected multiple SARS-COV-2 RBD lineages that have never been observed in patient samples in 9 sewersheds located in 3 states in the USA. These cryptic lineages contained between 4 to 24 amino acid substitutions in the RBD and were observed intermittently in the sewersheds in which they were found for as long as 14 months. Many of the amino acid substitutions in these lineages occurred at residues also mutated in the Omicron variant of concern (VOC), often with the same substitutions. One of the sewersheds contained a lineage that appeared to be derived from the Alpha VOC, but the majority of the lineages appeared to be derived from pre-VOC SARS-COV-2 lineages. Specifically, several of the cryptic lineages from New York City appeared to be derived from a common ancestor that most likely diverged in early 2020. While the source of these cryptic lineages has not been resolved, it seems increasingly likely that they were derived from long-term patient infections or animal reservoirs. Our findings demonstrate that SARS-COV-2 genetic diversity is greater than what is commonly observed through routine SARS-CoV-2 surveillance. Wastewater sampling may more fully capture SARS-CoV-2 genetic diversity than patient sampling and could reveal new VOCs before they emerge in the wider human population.


Subject(s)
COVID-19 , SARS-CoV-2 , Animals , Humans , SARS-CoV-2/genetics , Wastewater , COVID-19/epidemiology , Genetic Variation
10.
Cell Mol Immunol ; 19(12): 1392-1399, 2022 Dec.
Article in English | MEDLINE | ID: covidwho-2077039

ABSTRACT

The new predominant circulating SARS-CoV-2 variant, Omicron, can robustly escape current vaccines and neutralizing antibodies. Although Omicron has been reported to have milder replication and disease manifestations than some earlier variants, its pathogenicity in different age groups has not been well elucidated. Here, we report that the SARS-CoV-2 Omicron BA.1 sublineage causes elevated infection and lung pathogenesis in juvenile and aged hamsters, with more body weight loss, respiratory tract viral burden, and lung injury in these hamsters than in adult hamsters. Juvenile hamsters show a reduced interferon response against Omicron BA.1 infection, whereas aged hamsters show excessive proinflammatory cytokine expression, delayed viral clearance, and aggravated lung injury. Early inhaled IFN-α2b treatment suppresses Omicron BA.1 infection and lung pathogenesis in juvenile and adult hamsters. Overall, the data suggest that the diverse patterns of the innate immune response affect the disease outcomes of Omicron BA.1 infection in different age groups.


Subject(s)
COVID-19 Drug Treatment , COVID-19 , Interferon-alpha , Lung Injury , Animals , Cricetinae , Antibodies, Neutralizing/therapeutic use , Antibodies, Viral , Antiviral Agents , COVID-19/pathology , Interferon-alpha/therapeutic use , Lung Injury/virology , Mesocricetus , SARS-CoV-2
11.
Proc Natl Acad Sci U S A ; 119(34): e2204256119, 2022 08 23.
Article in English | MEDLINE | ID: covidwho-1991767

ABSTRACT

Antibody therapeutics for the treatment of COVID-19 have been highly successful. However, the recent emergence of the Omicron variant has posed a challenge, as it evades detection by most existing SARS-CoV-2 neutralizing antibodies (nAbs). Here, we successfully generated a panel of SARS-CoV-2/SARS-CoV cross-neutralizing antibodies by sequential immunization of the two pseudoviruses. Of the potential candidates, we found that nAbs X01, X10, and X17 offer broad neutralizing potential against most variants of concern, with X17 further identified as a Class 5 nAb with undiminished neutralization against the Omicron variant. Cryo-electron microscopy structures of the three antibodies together in complex with each of the spike proteins of the prototypical SARS-CoV, SARS-CoV-2, and Delta and Omicron variants of SARS-CoV-2 defined three nonoverlapping conserved epitopes on the receptor-binding domain. The triple-antibody mixture exhibited enhanced resistance to viral evasion and effective protection against infection of the Beta variant in hamsters. Our findings will aid the development of antibody therapeutics and broad vaccines against SARS-CoV-2 and its emerging variants.


Subject(s)
Antibodies, Neutralizing , Antibodies, Viral , Epitopes , SARS-CoV-2 , Severe acute respiratory syndrome-related coronavirus , Animals , Antibodies, Neutralizing/immunology , Antibodies, Viral/immunology , COVID-19 Vaccines/immunology , Conserved Sequence , Cricetinae , Cryoelectron Microscopy , Epitopes/immunology , Humans , Mice , Neutralization Tests , Severe acute respiratory syndrome-related coronavirus/immunology , SARS-CoV-2/immunology , Spike Glycoprotein, Coronavirus/genetics
12.
Sci Total Environ ; 838(Pt 3): 156193, 2022 Sep 10.
Article in English | MEDLINE | ID: covidwho-1852053

ABSTRACT

During the COVID-19 pandemic, the use of chlorine-based disinfectants has surged due to their excellent performance and cost-effectiveness in intercepting the spread of the virus and bacteria in water and air. Many authorities have demanded strict chlorine dosage for disinfection to ensure sufficient chlorine residual for inactivating viruses and bacteria while not posing harmful effects to humans as well as the environment. Reliable chlorine sensing techniques have therefore become the keys to ensure a balance between chlorine disinfection efficiency and disinfection safety. Up to now, there is still a lack of comprehensive review that collates and appraises the recently available techniques from a practical point of view. In this work, we intend to present a detailed overview of the recent advances in monitoring chlorine in both dissolved and gaseous forms aiming to present valuable information in terms of method accuracy, sensitivity, stability, reliability, and applicability, which in turn guides future sensor development. Data on the analytical performance of different techniques and environmental impacts associated with the dominated chemical-based techniques are thus discussed. Finally, this study concludes with highlights of gaps in knowledge and trends for future chlorine sensing development. Due to the increasing use of chlorine in disinfection and chemical synthesis, we believe the information present in this review is a relevant and timely resource for the water treatment industry, healthcare sector, and environmental organizations.


Subject(s)
COVID-19 , Disinfectants , Water Purification , Bacteria , COVID-19/epidemiology , Chlorides , Chlorine , Disinfection/methods , Halogenation , Humans , Pandemics , Reproducibility of Results , Water Purification/methods
15.
Environ Int ; 158: 106979, 2022 01.
Article in English | MEDLINE | ID: covidwho-1517151

ABSTRACT

Ambient concentrations of volatile organic compounds (VOCs) vary with emission rates, meteorology, and chemistry. Conventional positive matrix factorization (PMF) loses information because of dilution variations and chemical losses. Multiply improved PMF incorporates the ventilation coefficient, and total solar radiation or oxidants to reduce the effects of dispersion and chemical loss. These methods were applied to hourly speciated VOC data from November 2019 to March 2020 including during the COVID-19 shutdown. Various comparisons were made to assess the influences of these fluctuation drivers by time of day. Dispersion normalized PMF (DN-PMF) reduced the dispersion variations. Dispersion-radiation normalized PMF (DRN-PMF) reduced the impact of chemical loss, especially at night, which was better than Dispersion-Ox normalized PMF (DON-PMF). The conditional bivariate probability function (CBPF) plots of DRN-PMF results were consist with actual source locations. The DN-PMF, DRN-PMF, and DON-PMF results were consistent between 10:00 and 15:00, suggesting dispersion was significantly more influential than photochemical reactions during these times. The DRN-PMF results indicated that the highest VOC contributors during the COVID-19 shutdown were liquefied petroleum gas (LPG) (28.8%), natural gas (25.2%), and pulverized coal boilers emissions (19.6%). Except for petrochemical-related enterprises and LPG, the contribution concentrations of all other sources decreased substantially during the COVID-19 shutdown, by 94.7%, 90.6%, and 86.8% for vehicle emissions, gasoline evaporation, and the mixed source of diesel evaporation and solvent use, respectively. Controlling the use of motor vehicles and related volatilization of diesel fuel and gasoline can be effective in controlling VOCs in the future.


Subject(s)
Air Pollutants , COVID-19 , Volatile Organic Compounds , Air Pollutants/analysis , China , Environmental Monitoring , Humans , SARS-CoV-2 , Vehicle Emissions/analysis , Volatile Organic Compounds/analysis
16.
Pharmacol Res ; 174: 105955, 2021 12.
Article in English | MEDLINE | ID: covidwho-1487920

ABSTRACT

Severe Coronavirus Disease 2019 (COVID-19) is characterized by numerous complications, complex disease, and high mortality, making its treatment a top priority in the treatment of COVID-19. Integrated traditional Chinese medicine (TCM) and western medicine played an important role in the prevention, treatment, and rehabilitation of COVID-19 during the epidemic. However, currently there are no evidence-based guidelines for the integrated treatment of severe COVID-19 with TCM and western medicine. Therefore, it is important to develop an evidence-based guideline on the treatment of severe COVID-19 with integrated TCM and western medicine, in order to provide clinical guidance and decision basis for healthcare professionals, public health personnel, and scientific researchers involved in the diagnosis, treatment, and care of COVID-19 patients. We developed and completed the guideline by referring to the standardization process of the "WHO handbook for guideline development", the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system, and the Reporting Items for Practice Guidelines in Healthcare (RIGHT).


Subject(s)
Antiviral Agents/therapeutic use , COVID-19 Drug Treatment , Drugs, Chinese Herbal/therapeutic use , Infectious Disease Medicine/trends , Medicine, Chinese Traditional/trends , SARS-CoV-2/drug effects , Antiviral Agents/adverse effects , COVID-19/diagnosis , COVID-19/virology , Consensus , Delphi Technique , Drugs, Chinese Herbal/adverse effects , Evidence-Based Medicine/trends , Host-Pathogen Interactions , Humans , Patient Acuity , SARS-CoV-2/pathogenicity , Treatment Outcome
17.
Drug Discov Today ; 27(2): 390-400, 2022 02.
Article in English | MEDLINE | ID: covidwho-1487687

ABSTRACT

The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the unprecedented COVID-19 pandemic, which has infected over 178 million people worldwide. Even with new vaccines, global herd immunity will not be reached soon. New cases and viral variants are being reported at an alarming rate. Effective antiviral treatment is urgently needed. Patients with severe COVID-19 suffer from life-threatening respiratory failure due to acute respiratory distress syndrome in their lungs, a leading cause of COVID-19 mortality. This lung hyper-inflammation is induced by virus-caused massive tissue damage that is associated with uncontrolled cytokine release, known as a cytokine storm, through JAK/STAT signaling pathways. Here, we review the FDA-approved JAK inhibitors that are being clinically evaluated and repurposed for the treatment of patients with severe COVID-19 by calming SARS-CoV-2 infection.


Subject(s)
Antiviral Agents/therapeutic use , COVID-19 Drug Treatment , COVID-19/complications , Cytokine Release Syndrome/drug therapy , Cytokine Release Syndrome/etiology , Janus Kinase 2/antagonists & inhibitors , Protein Kinase Inhibitors/therapeutic use , STAT3 Transcription Factor/antagonists & inhibitors , Signal Transduction/drug effects , Animals , Humans
19.
Nat Commun ; 12(1): 4396, 2021 07 20.
Article in English | MEDLINE | ID: covidwho-1387353

ABSTRACT

Rapid development of antisense therapies can enable on-demand responses to new viral pathogens and make personalized medicine for genetic diseases practical. Antisense phosphorodiamidate morpholino oligomers (PMOs) are promising candidates to fill such a role, but their challenging synthesis limits their widespread application. To rapidly prototype potential PMO drug candidates, we report a fully automated flow-based oligonucleotide synthesizer. Our optimized synthesis platform reduces coupling times by up to 22-fold compared to previously reported methods. We demonstrate the power of our automated technology with the synthesis of milligram quantities of three candidate therapeutic PMO sequences for an unserved class of Duchenne muscular dystrophy (DMD). To further test our platform, we synthesize a PMO that targets the genomic mRNA of SARS-CoV-2 and demonstrate its antiviral effects. This platform could find broad application not only in designing new SARS-CoV-2 and DMD antisense therapeutics, but also for rapid development of PMO candidates to treat new and emerging diseases.


Subject(s)
Chemistry Techniques, Synthetic/instrumentation , Chemistry, Pharmaceutical/instrumentation , High-Throughput Screening Assays/instrumentation , Morpholinos/chemical synthesis , Oligonucleotides, Antisense/chemical synthesis , Animals , COVID-19/virology , Chlorocebus aethiops , Communicable Diseases, Emerging/drug therapy , Communicable Diseases, Emerging/microbiology , Disease Models, Animal , High-Throughput Screening Assays/methods , Humans , Morpholinos/pharmacology , Morpholinos/therapeutic use , Muscular Dystrophy, Duchenne/drug therapy , Muscular Dystrophy, Duchenne/genetics , Oligonucleotides, Antisense/pharmacology , Oligonucleotides, Antisense/therapeutic use , Precision Medicine/methods , RNA, Messenger/antagonists & inhibitors , RNA, Viral/antagonists & inhibitors , SARS-CoV-2/genetics , Time Factors , Vero Cells , COVID-19 Drug Treatment
20.
Front Immunol ; 12: 693579, 2021.
Article in English | MEDLINE | ID: covidwho-1337640

ABSTRACT

Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is a newly emerging, highly transmitted and pathogenic coronavirus that has caused global public health events and economic crises. As of March 4, 2021, more than 100 million people have been infected, more than 2 million deaths have been reported worldwide, and the numbers are continuing to rise. To date, a specific drug for this lethal virus has not been developed to date, and very little is currently known about the immune evasion mechanisms of SARS-CoV-2. The aim of this review was to summarize and sort dozens of published studies on PubMed to explore the pathogenic features of SARS-CoV-2, as well as the possible immune escape mechanisms of this virus.


Subject(s)
COVID-19/immunology , SARS-CoV-2/physiology , Severe Acute Respiratory Syndrome/immunology , Animals , COVID-19/epidemiology , Host-Pathogen Interactions , Humans , Immune Evasion , Pandemics
SELECTION OF CITATIONS
SEARCH DETAIL